S&P 500   4,299.64 (+0.06%)
DOW   34,089.17 (+0.52%)
QQQ   330.76 (-0.69%)
AAPL   172.99 (-0.12%)
MSFT   291.84 (-0.56%)
META   178.00 (-1.60%)
GOOGL   120.91 (-0.96%)
AMZN   142.66 (-0.36%)
TSLA   923.32 (-0.50%)
NVDA   187.19 (-1.64%)
NIO   20.75 (-2.58%)
BABA   92.30 (-2.02%)
AMD   99.14 (-1.85%)
MU   63.67 (-1.59%)
T   18.67 (+1.52%)
CGC   3.63 (-4.97%)
F   16.32 (+0.00%)
GE   79.64 (-0.21%)
DIS   124.42 (+0.13%)
AMC   23.64 (-2.35%)
PYPL   101.37 (-0.14%)
PFE   49.74 (-0.02%)
NFLX   245.71 (-1.36%)
S&P 500   4,299.64 (+0.06%)
DOW   34,089.17 (+0.52%)
QQQ   330.76 (-0.69%)
AAPL   172.99 (-0.12%)
MSFT   291.84 (-0.56%)
META   178.00 (-1.60%)
GOOGL   120.91 (-0.96%)
AMZN   142.66 (-0.36%)
TSLA   923.32 (-0.50%)
NVDA   187.19 (-1.64%)
NIO   20.75 (-2.58%)
BABA   92.30 (-2.02%)
AMD   99.14 (-1.85%)
MU   63.67 (-1.59%)
T   18.67 (+1.52%)
CGC   3.63 (-4.97%)
F   16.32 (+0.00%)
GE   79.64 (-0.21%)
DIS   124.42 (+0.13%)
AMC   23.64 (-2.35%)
PYPL   101.37 (-0.14%)
PFE   49.74 (-0.02%)
NFLX   245.71 (-1.36%)
S&P 500   4,299.64 (+0.06%)
DOW   34,089.17 (+0.52%)
QQQ   330.76 (-0.69%)
AAPL   172.99 (-0.12%)
MSFT   291.84 (-0.56%)
META   178.00 (-1.60%)
GOOGL   120.91 (-0.96%)
AMZN   142.66 (-0.36%)
TSLA   923.32 (-0.50%)
NVDA   187.19 (-1.64%)
NIO   20.75 (-2.58%)
BABA   92.30 (-2.02%)
AMD   99.14 (-1.85%)
MU   63.67 (-1.59%)
T   18.67 (+1.52%)
CGC   3.63 (-4.97%)
F   16.32 (+0.00%)
GE   79.64 (-0.21%)
DIS   124.42 (+0.13%)
AMC   23.64 (-2.35%)
PYPL   101.37 (-0.14%)
PFE   49.74 (-0.02%)
NFLX   245.71 (-1.36%)
S&P 500   4,299.64 (+0.06%)
DOW   34,089.17 (+0.52%)
QQQ   330.76 (-0.69%)
AAPL   172.99 (-0.12%)
MSFT   291.84 (-0.56%)
META   178.00 (-1.60%)
GOOGL   120.91 (-0.96%)
AMZN   142.66 (-0.36%)
TSLA   923.32 (-0.50%)
NVDA   187.19 (-1.64%)
NIO   20.75 (-2.58%)
BABA   92.30 (-2.02%)
AMD   99.14 (-1.85%)
MU   63.67 (-1.59%)
T   18.67 (+1.52%)
CGC   3.63 (-4.97%)
F   16.32 (+0.00%)
GE   79.64 (-0.21%)
DIS   124.42 (+0.13%)
AMC   23.64 (-2.35%)
PYPL   101.37 (-0.14%)
PFE   49.74 (-0.02%)
NFLX   245.71 (-1.36%)
NASDAQ:INO

Inovio Pharmaceuticals - INO Stock Forecast, Price & News

$2.71
-0.08 (-2.87%)
(As of 08/16/2022 11:10 AM ET)
Add
Compare
Today's Range
$2.68
$2.81
50-Day Range
$1.44
$2.79
52-Week Range
$1.38
$9.59
Volume
68,435 shs
Average Volume
6.53 million shs
Market Capitalization
$675.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75

Inovio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
106.1% Upside
$5.75 Price Target
Short Interest
Bearish
17.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.29mentions of Inovio Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$36,088 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.31) to ($1.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

674th out of 1,124 stocks

Surgical & Medical Instruments Industry

62nd out of 113 stocks

INO stock logo

About Inovio Pharmaceuticals (NASDAQ:INO) Stock

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Trading Up 1.9 %

Shares of INO Stock traded up $0.05 during trading hours on Monday, hitting $2.68. The company had a trading volume of 98,134 shares, compared to its average volume of 5,686,627. Inovio Pharmaceuticals has a 12 month low of $1.38 and a 12 month high of $9.74. The firm's fifty day moving average is $1.96 and its 200 day moving average is $2.66. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 0.06.

Inovio Pharmaceuticals (NASDAQ:INO - Get Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.18). The business had revenue of $0.78 million during the quarter, compared to analyst estimates of $0.52 million. Inovio Pharmaceuticals had a negative return on equity of 94.19% and a negative net margin of 16,775.78%. The firm's revenue was up 187.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.39) earnings per share. As a group, equities research analysts forecast that Inovio Pharmaceuticals will post -1.31 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on INO shares. Oppenheimer cut Inovio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 11th. Royal Bank of Canada started coverage on Inovio Pharmaceuticals in a research report on Tuesday, July 19th. They set a "sector perform" rating and a $4.00 price objective for the company. Cantor Fitzgerald cut their price objective on Inovio Pharmaceuticals from $6.00 to $3.00 in a research report on Wednesday, May 11th. Finally, StockNews.com upgraded Inovio Pharmaceuticals to a "sell" rating in a research note on Monday, May 23rd. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company's stock. According to MarketBeat.com, Inovio Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $5.75.

Insider Transactions at Inovio Pharmaceuticals

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 11,875 shares of the company's stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $2.66, for a total transaction of $31,587.50. Following the transaction, the director now owns 892,625 shares of the company's stock, valued at approximately $2,374,382.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.30% of the stock is owned by company insiders.

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Stock News Headlines

Two Appealing Biotech Stocks for Two Distinct investors (INO)
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Does Amarin Deserve a Spot in Your Portfolio after Earnings ? (INO)
Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio.
Inovio Pharmaceuticals (NASDAQ:INO) Trading Up 11.4%
Why Inovio Pharmaceuticals Is Gaining Today
After Slashing Costs, Is Inovio a Buy?
Inovio Pharmaceuticals (NASDAQ:INO) Stock Price Up 15.4%
RBC Capital Lowers Inovio Price Target As It Awaits This
Inovio to reduce its workforce by 18%
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Company Calendar

Last Earnings
8/09/2022
Today
8/16/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
317
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$5.75
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+112.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-303,660,000.00
Net Margins
-16,775.78%
Pretax Margin
-16,675.59%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$1.90 per share

Miscellaneous

Free Float
241,170,000
Market Cap
$675.87 million
Optionable
Optionable
Beta
0.88

Social Links


Key Executives

  • Dr. Jacqueline E. Shea Ph.D. (Age 56)
    CEO, Pres & Director
    Comp: $698.85k
  • Mr. Peter D. Kies (Age 59)
    Chief Financial Officer
    Comp: $686.51k
  • Dr. Laurent M. Humeau Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $672.26k
  • Ben Matone
    Director of Investor Relations
  • Mr. Robert L. Crotty J.D. (Age 48)
    Gen. Counsel
  • Ms. Asli Gevgilili
    Chief HR Officer
  • Mr. E. J. Brandreth MBA
    Sr. VP of Quality Assurance
  • Dr. Jeffrey Skolnik
    Sr. VP of Clinical Devel.
  • Mr. Robert J. Juba Jr.
    Sr. VP of Biological Manufacturing & Clinical Supply Management
  • Mr. Daniel Jordan
    Sr. VP of Device Manufacturing Operations













INO Stock - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price forecast for 2022?

5 brokers have issued 1-year price targets for Inovio Pharmaceuticals' stock. Their INO share price forecasts range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 106.1% from the stock's current price.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2022?

Inovio Pharmaceuticals' stock was trading at $4.99 on January 1st, 2022. Since then, INO shares have decreased by 44.1% and is now trading at $2.79.
View the best growth stocks for 2022 here
.

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our INO earnings forecast
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.18. The biopharmaceutical company earned $0.78 million during the quarter, compared to analysts' expectations of $0.52 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 94.19% and a negative net margin of 16,775.78%. The company's quarterly revenue was up 187.5% on a year-over-year basis. During the same period last year, the firm earned ($0.39) EPS.

When did Inovio Pharmaceuticals' stock split?

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (12.91%), Rafferty Asset Management LLC (0.83%), Northern Trust Corp (0.87%), Renaissance Technologies LLC (0.69%), UBS Group AG (0.26%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $2.79.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $695.83 million and generates $1.77 million in revenue each year. The biopharmaceutical company earns $-303,660,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

The company employs 317 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.

This page (NASDAQ:INO) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.